Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JYL
|
|||
| Drug Name |
Hu5F9-G4
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [1] | |
| B-cell non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1/2 | [2], [3] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [2], [3] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2], [3] | ||
| Company |
Forty Seven Menlo Park, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen CD47 (CD47) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.